Search

everythinglearnresearchcommunity

for

Search:↓

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Researchers created small amber particles for use in bioactive and biocompatible fibers that could help with skin and hair restoration and are safe for infant clothing.

New treatments like nanotechnology show promise in improving skin cancer therapy.

There is no gold standard treatment for hidradenitis suppurativa due to insufficient evidence.

Different treatments for Hidradenitis suppurativa range from antibiotics and hormonal therapies to surgery, depending on severity.

Immune cells in Hidradenitis suppurativa become more inflammatory and may be important for treatment targets.

Deoxycholic acid effectively reduces double chin fat with temporary side effects and high patient satisfaction.

Mice with enhanced regeneration abilities may help develop new regenerative medicine therapies.

Panax ginseng is generally safe with mild side effects and may have health benefits, but more research is needed.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

Swiss experts recommend specific guidelines for diagnosing and treating hidradenitis suppurativa to improve patient care.

Many treatments for hair loss show potential, but more testing is needed to confirm their effectiveness. Only minoxidil for women and minoxidil and finasteride for men are FDA approved.

Almost all patients with chronic kidney disease not yet on dialysis have at least one skin problem.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Laser treatment and deroofing are effective options for hidradenitis suppurativa.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

People living with HIV in Turkey often have skin conditions, which are more common in advanced HIV stages and may help in diagnosing the infection.

Regenerative cellular therapies show promise for treating non-scarring hair loss but need more research.

The enzymes 5α-reductase and 3α/β-hydroxysteroid oxidoreductase help create brain-active substances from progesterone and testosterone, which could be used for treatment, but more research is needed to ensure their safety and effectiveness.

The flexible fixed-sequence testing method allows for more effective evaluation of multiple goals in a clinical trial while controlling the risk of false positives.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

The document concludes that PK/PD modeling is important for determining the safe and effective dosages of drugs.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.

Minoxidil effectively treats female pattern hair loss.

Topical minoxidil helps treat female pattern hair loss, but more research needed for other treatments.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.